Dr. Anna Cartier received her PhD in Infection Biology from the Karolinska Institute, Stockholm, Sweden in 2004. Dr. Cartier then continued her postgraduate studies as a postdoctoral fellow and assistant project scientist at UCSD where her primary interests focused on identifying de-ubiquitinating enzymes that regulate neuronal plasticity and are involved in neurodegenerative disorders. Dr. Cartier has a multidisciplinary background with a focus in the field of neurosciences, and strong technical skills in molecular and cell biology, biochemistry, and imaging techniques. During her scientific career, Dr. Cartier has developed research programs based on her original ideas leading to several first author publications, and has gained expertise working with transgenic pre-clinical models. Dr. Cartier joined ICB International, Inc. in October of 2012 as associate director where she oversees all experimental aspects pertaining to pre-clinical models and picobody testing.